Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40%

Earlier detection and treatment optimization enabled by CNSide may reduce overall LM-related healthcare costs by ~40% (33%-47%) Potential savings are driven by earlier therapeutic intervention, ...
ascopubs.org

The clinical utility of a circulating tumor cell based cerebrospinal fluid assay in the diagnosis and molecular analysis of leptomeningeal disease in patients with metastatic ...

Comparing rates of immune checkpoint inhibitor toxicity in different treatment settings (neoadjuvant, adjuvant, and palliative) in non-small cell lung cancer (NSCLC): A meta-analysis of phase III ...
The Scientist

Cerebrospinal Fluid Reflects Disease-Specific Immune Profiles

Using single-cell sequencing, researchers found distinct immune profiles in different CNS tumors, highlighting its potential as a prognostic tool.
ascopubs.org

Systematic Review of Cerebrospinal Fluid Biomarker Discovery in Neuro-Oncology: A Roadmap to Standardization and Clinical Application

Impact of Broadening Trial Eligibility Criteria on the Inclusion of Patients With Brain Metastases in Cancer Clinical Trials: Time Series Analyses for 2012-2022 Effective diagnosis, prognostication, ...